Mandate

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.

The debt financing comprised fully underwritten senior secured bonds totalling EUR 225 million, along with a super senior revolving credit facility.

Vivicta serves customers with primarily an outsourcing business model focusing on cloud, data, applications and infrastructure, and employs more than 7,000 people globally. As a standalone company going forward, Tietoevry Tech Services is being rebranded under the name Vivicta.

Vinge’s team consisted, of among others, Christina Kokko, Per Kling, Vilhelm Rondahl, Saga Meyer Viklund and Linn Aho (M&A), Arvid Weimers, Felix Möller, Nour Makie, August Ahlin, William Carlberg Johansson and Julia Gudmundsson (Banking and Finance), Martin Boström, Fredrika Hjelmberg, Carla Håkansson and Mario Saad (Corporate Commercial), Madelene Andersson (Real Estate), Daniel Wendelsson, Fredrik Hellström and Hilda Ivarsson (FDI).

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026